<DOC>
	<DOCNO>NCT01626872</DOCNO>
	<brief_summary>The objective study evaluate long-term safety , tolerability , efficacy MP-214 patient schizophrenia .</brief_summary>
	<brief_title>Long-Term Study MP-214 Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Written inform consent obtain patient completion Study A002A4 Patients complete A002A4 study Patients experience ongoing , uncontrolled , clinically significant adverse event ( AEs ) , judge investigator ( subinvestigator )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Mental Disorder</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>